跳转至内容
Merck
CN
  • Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?

Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?

Cerebrovascular diseases (Basel, Switzerland) (2007-11-29)
P H A Halkes, A Algra
摘要

In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke. In patients with atrial fibrillation, the secondary preventive treatment of first choice is oral anticoagulation with an aimed international normalised ratio between 2.0 and 3.0. In patients without a cardiac source of embolism, a combination therapy of low-dose aspirin and dipyridamole 200 mg twice daily is the treatment of choice. These treatment strategies do however not prevent all recurrent strokes or vascular complications, and research for more effective strategies is warranted.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
双嘧达莫, ≥98% (HPLC)
双嘧达莫, European Pharmacopoeia (EP) Reference Standard
双嘧达莫, European Pharmacopoeia (EP) Reference Standard